Compare MNDO & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNDO | AIMD |
|---|---|---|
| Founded | 1995 | 1984 |
| Country | Israel | United States |
| Employees | N/A | 41 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0M | 17.5M |
| IPO Year | 2000 | N/A |
| Metric | MNDO | AIMD |
|---|---|---|
| Price | $0.96 | $1.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.8K | ★ 884.9K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 20.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $0.45 |
| 52 Week High | $1.50 | $4.50 |
| Indicator | MNDO | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 47.91 |
| Support Level | $0.87 | $1.56 |
| Resistance Level | $1.24 | $2.51 |
| Average True Range (ATR) | 0.05 | 0.50 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 45.21 | 18.64 |
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.